Literature DB >> 20089699

The direction of plasma membrane exchange between lymphocytes and accessory cells by trogocytosis is influenced by the nature of the accessory cell.

Sandrine Daubeuf1, Margaret A Lindorfer, Ronald P Taylor, Etienne Joly, Denis Hudrisier.   

Abstract

Exchange of plasma membrane fragments, including cell-surface proteins and lipids, in conjugates formed between lymphocytes and their cellular partners is a field of intense investigation. Apart from its natural occurrence during Ag recognition, the process of membrane transfer can be triggered in experimental or therapeutic settings when lymphocytes targeted by Abs are conjugated to FcgammaR-expressing accessory cells. The direction of membrane capture (i.e., which of the two cells is going to donate or accept plasma membrane fragments) can have important functional consequences, such as insensitivity of tumor cells to treatment by therapeutic mAbs. This effect, called antigenic modulation or shaving, occurs as a result of a process in which the FcgammaR-expressing cells remove the mAb and its target protein from the tumor cells. We therefore analyzed this process in conjugates formed between various FcgammaR-expressing cells and a series of normal or tumor T and B cells opsonized with different Abs capable of triggering membrane exchange (including the therapeutic Ab rituximab). Our results show that the direction of membrane capture is dictated by the identity of the FcgammaR-expressing cell, much more so than the type of lymphocyte or the Ab used. We found that monocytes and macrophages are prone to be involved in bidirectional trogocytosis with opsonized target cells, a process they can perform in parallel to phagocytosis. Our observations open new perspectives to understand the mechanisms involved in trogocytosis and may contribute to optimization of Ab-based immunotherapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20089699     DOI: 10.4049/jimmunol.0901570

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  30 in total

1.  Horizontal gene transfer from macrophages to ischemic muscles upon delivery of naked DNA with Pluronic block copolymers.

Authors:  Vivek Mahajan; Zagit Gaymalov; Daria Alakhova; Richa Gupta; Irving H Zucker; Alexander V Kabanov
Journal:  Biomaterials       Date:  2015-10-09       Impact factor: 12.479

2.  Trogocytosis-Mediated Intracellular Signaling in CD4+ T Cells Drives TH2-Associated Effector Cytokine Production and Differentiation.

Authors:  Jim Reed; Scott A Wetzel
Journal:  J Immunol       Date:  2019-04-08       Impact factor: 5.422

3.  Transfer of the human NKG2D ligands UL16 binding proteins (ULBP) 1-3 is related to lytic granule release and leads to ligand retransfer and killing of ULBP-recipient natural killer cells.

Authors:  Sheila López-Cobo; Gema Romera-Cárdenas; Eva M García-Cuesta; Hugh T Reyburn; Mar Valés-Gómez
Journal:  Immunology       Date:  2015-06-25       Impact factor: 7.397

Review 4.  Antibody-dependent cellular cytotoxicity in HIV infection.

Authors:  Donald N Forthal; Andrés Finzi
Journal:  AIDS       Date:  2018-11-13       Impact factor: 4.177

5.  Infection biology: Nibbled to death.

Authors:  Nancy Guillén
Journal:  Nature       Date:  2014-04-09       Impact factor: 49.962

6.  CD4(+) T cell-released exosomes inhibit CD8(+) cytotoxic T-lymphocyte responses and antitumor immunity.

Authors:  Haifeng Zhang; Yufeng Xie; Wei Li; Rajni Chibbar; Sidong Xiong; Jim Xiang
Journal:  Cell Mol Immunol       Date:  2010-12-13       Impact factor: 11.530

7.  Imprinting of lymphocytes with melanoma antigens acquired by trogocytosis facilitates identification of tumor-reactive T cells.

Authors:  Galit Eisenberg; Ronny Uzana; Aviad Pato; Shoshana Frankenburg; Sharon Merims; Eitan Yefenof; Soldano Ferrone; Tamar Peretz; Arthur Machlenkin; Michal Lotem
Journal:  J Immunol       Date:  2013-04-26       Impact factor: 5.422

8.  CD20+ T cells have a predominantly Tc1 effector memory phenotype and are expanded in the ascites of patients with ovarian cancer.

Authors:  Marco de Bruyn; Valerie R Wiersma; Maartje C A Wouters; Douwe F Samplonius; Harry G Klip; Wijnand Helfrich; Hans W Nijman; Paul Eggleton; Edwin Bremer
Journal:  Oncoimmunology       Date:  2015-03-19       Impact factor: 8.110

9.  Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia.

Authors:  Nisar A Baig; Ronald P Taylor; Margaret A Lindorfer; Amy K Church; Betsy R LaPlant; Adam M Pettinger; Tait D Shanafelt; Grzegorz S Nowakowski; Clive S Zent
Journal:  J Immunol       Date:  2014-01-15       Impact factor: 5.422

10.  Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells.

Authors:  Clive S Zent; Ronald P Taylor; Margaret A Lindorfer; Paul V Beum; Betsy LaPlant; Wenting Wu; Timothy G Call; Deborah A Bowen; Michael J Conte; Lori A Frederick; Brian K Link; Sue E Blackwell; Suresh Veeramani; Nisar A Baig; David S Viswanatha; George J Weiner; Thomas E Witzig
Journal:  Am J Hematol       Date:  2014-04-26       Impact factor: 10.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.